Merck has agreed to a $10-billion buyout of Verona Pharma and its first-in-class, potential COPD blockbuster Ohtuvayre.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss of revenue once Keytruda patent protection lapses.

US drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung diseases, the Financial Times reported on Wednesday.Merck will pay $107 per ...

Merck (MRK) is buying Verona Pharma (VRNA) in a $10 billion deal. Linda Yaccarino is stepping down as CEO of X (formerly Twitter) after two years leading the social media platform owned by Elon Musk.

The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential.

Meanwhile, Merck has struck a roughly $10 billion deal to buy lung disease focused biotech Verona Pharma. This is Merck's biggest acquisition in two years.

Merck KGaA has shed light on the failure in one lupus cohort, while pointing to secondary endpoint wins as proof that enpatoran still deserves a shot.

Merck Manuals launches AI-powered search, offering patients fast, trusted answers from its widely used medical manuals and resources.

[LONDON] Merck is nearing a US$10 billion deal to buy lung diseases focussed Verona Pharma, as the US drugmaker is eyeing deals to offset the upcoming patent expiry of its blockbuster cancer drug, the ...

Robert F. Kennedy Jr.’s vaccine advisory committee recommended Merck & Co.’s shot to prevent newborns from getting RSV, alleviating some concerns that the new Department of Health and ...

Today's biotech news includes vaccine policy frays, a CDC nominee in the hotseat, and NIH grant awards drying up.